0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Estrous Cycle Delay and Inhibition of Gonadotropin and Prolactin Release during Sympathetic Nerve Degeneration after Superior Cervical Ganglionectomy of Rats

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The changes in the activity of the pituitary-gonadal axis during sympathetic nerve degeneration after superior cervical ganglionectomy (SCGx) were examined in female rats. In a first experiment SCGx performed at 24.00 h of diestrus II, 17 h in advance to the critical period for gonadotropin and prolactin (PRL) release, caused a delay of 1 day or more in estrous cyclicity, while SCGx at 24.00 h on estrus did not modify the estrous cycle. In a second experiment ovariectomized rats injected subcuta-neously with estradiol-progesterone or vehicle were subjected to SCGx 17 h before the expected maxima in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and PRL serum levels. A significant decrease of serum gonadotropin and PRL concentration was found in SCGx, steroid-treated rats. In a third experiment groups of rats injected with estradiol-progesterone and killed at 15.00, 16.00, 17.00, or 18.00 h at or around the time of maximal FSH, LH, and PRL release were used. SCGx performed 17 h before killing caused a generally depressive effect of LH, FSH, and PRL release. In a fourth experiment ovariectomized rats were subjected to pinealectomy and, 1 week later, to estradiol-progesterone treatment and SCGx as in experiment 2. Pinealectomy did not modify the depression of steroid-induced LH, FSH, and PRL release found during wallerian degeneration of sympathetic nerves after SCGx. In a fifth experiment the effect of α<sub>1</sub>- and/or β-adrenoceptor blockade on SCGx-induced inhibition of hormone release was assessed in estradiol-progesterone treated, spayed rats. During anterograde degeneration (i.e., 17 h after SCGx) injection of the α<sub>1</sub>-adrenergic blocker prazosin counteracted the impaired release of LH, FSH, and PRL, while β-adrenoceptor blockade by giving propranolol did not modify hormone secretion. In a sixth experiment groups of rats injected with estradiol-progesterone and killed at 16.00, 17.00, or 18.00 h were subjected to SCGx 17 h before killing, the rats received prazosin or the α<sub>1</sub>/α<sub>2</sub>-adrenoceptor blocker phentolamine 45 min before sacrifice. Both drugs were found to be equipotent in counteracting the SCGx effect on gonadotropin and PRL release. These results demonstrate that the coincidence of anterograde degeneration of sympathetic terminals in the superior cervical ganglion field of projection with the spontaneous or induced gonadotropin and PRL release in female rats (1) disrupts temporarily estrous cyclicity and (2) decreases estradiol-progesterone-induced LH, FSH, and PRL release through a pineal gland independent mechanism. Noradrenergic transmitter release from degenerating sympathetic nerves acts via α<sub>1</sub>-adrenoceptors to decrease gonadotropin and PRL secretion.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1989
          1989
          02 April 2008
          : 50
          : 1
          : 59-65
          Affiliations
          Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Argentina
          Article
          125202 Neuroendocrinology 1989;50:59–65
          10.1159/000125202
          2502728
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Original Paper

          Comments

          Comment on this article